Browse News
Filter News
Found 41 articles
-
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
8/9/2022
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the second quarter ended June 30, 2022, and provided a business update.
-
Powered by its blockbuster checkpoint inhibitor Keytruda, Merck is forecasting a potential of more than 80 new regulatory approvals in oncology through 2028.
-
Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline
6/7/2022
Merck, known as MSD outside the United States and Canada, will provide a detailed overview of the company’s oncology portfolio and pipeline at an investor event at the 2022 American Society for Clinical Oncology Annual Meeting in Chicago at 7 a.m. CT/8 a.m. ET.
-
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
6/2/2022
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the 2022 Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 11:00 a.m. ET in New York.
-
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
5/31/2022
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s investigational new drug (IND) application for its lead product candidate, JANX007.
-
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
5/10/2022
Janux Therapeutics, Inc., a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, reported financial results for the first quarter ended March 31, 2022 and provided a business update.
-
Several biopharma companies are closing out the month of April with expansions to facilities, including a $3 billion investment to develop next-generation life science ecosystems.
-
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
4/26/2022
Janux Therapeutics today announced its upcoming presentation of preclinical data for the Company’s two lead TRACTr programs, PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008).
-
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
3/18/2022
Janux Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
-
Gennao Bio Strengthens Board of Directors with Appointments of Peter Thompson, M.D., and Bradley Campbell
3/17/2022
Gennao Bio today announced the appointments of Peter Thompson, M.D., and Bradley Campbell to its Board of Directors.
-
TROP2 Directed Antibody Drug Conjugate Targeted Cancer Therapy Insight
3/15/2022
The advent of next generation sequencing has led to identification of multiple novel molecular alterations in cancer.
-
Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer
3/1/2022
Janux Therapeutics, Inc. today announced the appointment of Byron Robinson, Ph.D., J.D., as Chief Strategy Officer.
-
Janux Therapeutics to Present at Upcoming March Investor Conferences
3/1/2022
Janux Therapeutics, Inc. today announced that Janux management will participate in three upcoming investor conferences.
-
Anti TROP2 Monoclonal Antibody Immunotherapy Market 2026
2/9/2022
The aberrant Trop-2 overexpression is associated in several solid tumors including colorectal, lung cancer, and breast cancers.
-
ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.
-
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
1/20/2022
ImmPACT Bio USA, Inc., a clinical-stage company developing transformative logic-gate based chimeric antigen receptor T-cell therapies for treating cancer, announced it has closed $111 million in Series B financing, led by venBio Partners along with co-leads Foresite Capital and Decheng Capital.
-
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
1/5/2022
Janux Therapeutics, Inc. announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13.
-
Global TROP2 Antibody Drug Conjugate Market Clinical Trials Insight
12/2/2021
Trophoblast cell surface antigen-2 (Trop-2) is a 35-kDa transmembrane glycoprotein and calcium signal transducer encoded by the TACSTD2 gene, and is structurally related to epithelial cell adhesion molecule (EpCAM).
-
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
11/9/2021
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the quarter ended September 30, 2021.
-
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
11/8/2021
Janux Therapeutics, Inc. today announced that Janux management will participate in fireside chats at two upcoming virtual investor conferences: Cowen’s 5th Annual IO Next Summit